Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that PD-L1 (CPS) >= 10 status confers therapeutic sensitivity to Dordaviprone in patients with Esophageal Adenocarcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy for for reimbursement as a treatment option for the first-line treatment of adult patients with unresectable or metastatic carcinoma of the oesophagus or HER2-negative gastro-osophageal junction adenocarcinoma whose tumors express PD-L1 with CPS >= 10.
This statement is based on a regulatory approval from the Health Service Executive:
Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy, for the first line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with CPS >= 10.
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2026-08-02 | Van Allen lab | Initial curation of into moalmanac-db |
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |
| 2023-06-01 | Health Service Executive | Indication approved for reimbursement. |